Geron Corporation is a clinical biopharmaceutical company headquartered in Foster City, California, focused on developing innovative therapies for myeloid hematologic neoplasms. The company's lead programs, including its proprietary telomerase inhibitor, aim to address significant unmet medical needs in the blood cancer landscape. With a strong pipeline and a commitment to cutting-edge hematology research, Geron is dedicated to improving treatment outcomes and transforming the lives of patients suffering from these challenging conditions. Show more

Location: 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, UNITED STATES, 94404, Suite 250, Foster City, CA, 94404, USA | Website: https://www.geron.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

874.5M

52 Wk Range

$1.04 - $3.09

Previous Close

$1.37

Open

$1.38

Volume

9,625,078

Day Range

$1.33 - $1.40

Enterprise Value

615.9M

Cash

78.12M

Avg Qtr Burn

-13.58M

Insider Ownership

0.10%

Institutional Own.

81.05%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
RYTELO™ (Imetelstat) (GRN163L) Details Myelodysplastic syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imetelstat (GRN163L) Details Myelofibrosis	Phase 3 Interim Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imetelstat (GRN163L) Details Myelodysplastic syndrome, Acute myeloid leukemia	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imetelstat (GRN163L)+ ruxolitinib Details Myelofibrosis	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.